Drug Name:
ATIVAN INJECTION CIV

Generic Name and Formulations:
Lorazepam 2mg/mL, 4mg/mL; soln for IV inj after dilution or IM inj; contains polyethylene glycol 400 in propylene glycol, benzyl alcohol.
Company:
Hikma Pharmaceuticals
Therapeutic Use:
Indications for ATIVAN INJECTION:
Preanesthetic to produce sedation, anxiety relief, and diminished recall of events related to surgery.
Adult:
Individualize. ≥18yrs: IM: Give 2 hours prior to surgery. 0.05mg/kg, max 4mg. IV: Give 15–20 minutes prior to surgery. 0.044mg/kg or 2mg total, whichever is lower, may increase dose to 0.05mg/kg up to max 4mg if diminished recall of events related to surgery is desired; >50yrs: max IV dose of 0.044mg/kg or 2mg total, whichever is lower.
Children:
<18yrs: not established.
Contraindications:
Acute narrow-angle glaucoma. Sleep apnea. Severe respiratory insufficiency (except as preanesthetic during mechanical ventilation). Intra-arterial injection. Premature infants.
Warnings/Precautions:
Risks from concomitant use with opioids; see Interactions. Monitor for respiratory depression and level of sedation; ensure availability of resuscitative equipment for ventilatory support. Fall risk. Critically ill. Limited pulmonary reserve. Hepatic or renal failure: not recommended; mild-to-moderate hepatic/renal disease: use with caution. Avoid extravasation. Outpatient endoscopy. Pediatric neurotoxicity. Neonates, infants: risk of gasping syndrome. Elderly. Labor & delivery, pregnancy (Cat.D), nursing mothers: not recommended.
Pharmacological Class:
Benzodiazepine.
Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS effects with alcohol, phenothiazines, barbiturates, antidepressants, and MAOIs. Caution with concomitant scopolamine, loxapine, clozapine, haloperidol, or other CNS depressant drugs. May be antagonized by oral contraceptives (may need to increase lorazepam dose). May be potentiated by probenecid or valproate (reduce lorazepam dose by 50%).
Adverse Reactions:
Respiratory depression/failure, hypotension, somnolence, headache, apnea, excessive sleepiness and drowsiness, inj site reaction, paradoxical reactions.
Generic Availability:
YES
How Supplied:
Single-use vials—10, 25; Multiple-dose vials (10mL)—10, 25
Indications for ATIVAN INJECTION:
Status epilepticus.
Adult:
Individualize. ≥18yrs: Give by IV inj. 4mg at a rate of 2mg/min; may repeat dose once in 10–15 minutes if seizures continue or recur.
Children:
<18yrs: not established.
Contraindications:
Acute narrow-angle glaucoma. Sleep apnea. Severe respiratory insufficiency (except as preanesthetic during mechanical ventilation). Intra-arterial injection. Premature infants.
Warnings/Precautions:
Risks from concomitant use with opioids; see Interactions. Monitor for respiratory depression and level of sedation; ensure availability of resuscitative equipment for ventilatory support. Fall risk. Critically ill. Limited pulmonary reserve. Hepatic or renal failure: not recommended; mild-to-moderate hepatic/renal disease: use with caution. Avoid extravasation. Outpatient endoscopy. Pediatric neurotoxicity. Neonates, infants: risk of gasping syndrome. Elderly. Labor & delivery, pregnancy (Cat.D), nursing mothers: not recommended.
Pharmacological Class:
Benzodiazepine.
Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS effects with alcohol, phenothiazines, barbiturates, antidepressants, and MAOIs. Caution with concomitant scopolamine, loxapine, clozapine, haloperidol, or other CNS depressant drugs. May be antagonized by oral contraceptives (may need to increase lorazepam dose). May be potentiated by probenecid or valproate (reduce lorazepam dose by 50%).
Adverse Reactions:
Respiratory depression/failure, hypotension, somnolence, headache, apnea, excessive sleepiness and drowsiness, inj site reaction, paradoxical reactions.
Generic Availability:
YES
How Supplied:
Single-use vials—10, 25; Multiple-dose vials (10mL)—10, 25
Renal and Urology News Articles
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Anemia
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetes
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Hemodialysis
- Hyperkalemia
- Hyperphosphatemia
- Hypertension
- Hyperuricemia
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Transplantation